A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM
Clinical trial NCT04967690 · UNKNOWN
Trial details
- NCT number
- NCT04967690
- Sponsor
- Double Bond Pharmaceutical AB
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-01-01
- Primary completion
- 2025-07-01
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.